Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pathol.2022.04.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Haemosiderotic fibrolipomatous tumour: an extremely unusual intraosseous presentation.
Pathology
February 2023
Imaging Queensland, Nambour, Qld, Australia.
Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms.
Histopathology
May 2016
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
In recent years, there have been several important refinements in the classification of cutaneous mesenchymal neoplasms, including the description of new tumour types, along with the identification of novel and recurrent molecular genetic findings. In addition to providing new insights into tumour biology, many of these advances have had significant clinical consequences with regard to diagnostics, management, and prognostication. Newly described entities include pseudomyogenic haemangioendothelioma, haemosiderotic fibrolipomatous tumour, and fibroblastic connective tissue naevus, which are reviewed in the context of the principal differential diagnoses and significant clinical implications.
View Article and Find Full Text PDF[Fourth edition of WHO classification tumours of soft tissue].
Ann Pathol
January 2015
Institut Bergonié, département de bio-pathologie, université de Bordeaux, 229, cours de l'Argonne, 33000 Bordeaux, France.
The new World Health Organization (WHO) classification of soft tissue tumours was published in 2013, 11years after the previous edition. This new classification includes several changes: newly included sections (gastrointestinal stromal tumors…), newly recognized entities (pseudomiogenic haemangioendothelioma, haemosiderotic fibrolipomatous tumour…), and new genetic and molecular data leading to better understanding and definition of tumours, and are useful as diagnostic tools. This brief review summarizes changes in this new edition of the WHO classification of tumours of soft tissue.
View Article and Find Full Text PDFWHO classification of soft tissue tumours: an update based on the 2013 (4th) edition.
Pathology
February 2014
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
The fourth edition of the World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone was published in February 2013, and serves to provide an updated classification scheme and reproducible diagnostic criteria for pathologists. Given the relative rarity of soft tissue tumours and the rapid rate of immunohistochemical and genetic/molecular developments (not infrequently facilitating recognition of new tumour entities), this updated text edited by a consensus group is important for both practising pathologists and oncologists. The 2013 WHO classification includes several changes in soft tissue tumour classification, including several new entities (e.
View Article and Find Full Text PDFTwo genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions.
J Pathol
April 2009
Department of Clinical Genetics, University Hospital, Lund, Sweden.
Myxoinflammatory fibroblastic sarcoma (MIFS) is a low-grade malignant neoplasm for which limited genetic information, including a t(1;10)(p22;q24) and amplification of chromosome 3 material, is available. To further characterize these aberrations, we have investigated eight soft tissue sarcomas diagnosed as MIFS, haemosiderotic fibrolipomatous tumour (HFT), myxoid spindle cell/pleomorphic sarcoma with MIFS features, and inflammatory malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma with prominent inflammation (IMFH) harbouring a t(1;10) or variants thereof and/or ring chromosomes with possible involvement of chromosome 3. Using chromosome banding, fluorescence in situ hybridization, array-based comparative genomic hybridization, global gene expression, and real-time quantitative PCR analyses, we identified the breakpoint regions on chromosomes 1 and 10, demonstrated and delineated the commonly amplified region on chromosome 3, and assessed the consequences of these alterations for gene expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!